骨代谢标志物在[223Ra]RaCl2治疗中与疾病范围的相关性及对总生存期的预测
前瞻性研究纳入55例接受镭-223治疗的转移性去势抵抗性前列腺癌患者,于每次给药前检测骨代谢标志物。基线Log2-CTX-MMP与Log2-BALP与总生存期相关,治疗期间CTX-MMP升高者总生存期显著短于稳定或下降者。
要点
- 骨代谢标志物与骨转移范围呈显著线性相关,但与骨扫描指数动态变化无显著关联。
- 基线Log2-CTX-MMP(HR=2.15)和Log2-BALP(HR=1.59)与总生存期相关。
- 治疗期间CTX-MMP升高者中位总生存期4个月,短于稳定或下降者的12个月(P<0.001)。
核心结论
- 骨代谢标志物与mCRPC患者骨转移范围及总生存期显著相关。
- 骨吸收标志物CTX-MMP是预测镭-223治疗结局的有前景的替代标志物,可能有助于改善患者选择和疗效评估。
研究设计与样本
- 前瞻性研究,纳入55例接受镭-223治疗的转移性去势抵抗性前列腺癌患者。
- 每次给药前采集血样,定量检测BALP、骨钙素、PINP、CTX、CTX-MMP、TRACP5b、RANKL、OPG和硬骨素。
- 临床结局包括治疗期间或治疗后闪烁显像进展、骨扫描指数变化、症状性骨骼事件发生和总生存期。
主要发现
- 骨转移范围与CTX-MMP、PINP、BALP和骨钙素之间存在显著线性关联。
- 骨扫描指数动态变化与骨代谢标志物之间未检测到显著关联。
- 队列中位总生存期为14个月(95%CI:10.7-16.8)。
- 基线Log2-CTX-MMP(HR=2.15,95%CI:1.1-4.1)和Log2-BALP(HR=1.59,95%CI:1.1-2.1)与总生存期相关。
- 治疗期间CTX-MMP升高者中位总生存期为4个月(95%CI:2.3-5.7),短于CTX-MMP稳定或下降者的12个月(95%CI:10.1-13.9),P<0.001。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The alpha-emitting radionuclide therapy [223Ra]RaCl2 (Radium-223) improves overall survival (OS) and time to symptomatic skeletal event (SSE) in patients with metastatic castration-resistant prostate cancer (mCRPC). Evidence suggests that the effect of Radium-223 is partly exerted through an impact on the surrounding bone matrix. We hypothesized that bone metabolism markers (BMM) could provide predictive information regarding response to Radium-223. Accordingly, the aim of this study was to investigate changes in BMM during Radium-223 therapy and evaluate association with clinical outcome. METHODS: Prospective study of BMM in patients with mCRPC receiving Radium-223. Blood samples were collected before each administration of Radium-223 and the following BMM were quantified; bone-specific alkaline phosphatase (BALP), osteocalcin, procollagen type I N-propeptide (PINP), C-terminal telopeptide of type I collagen (CTX), C-terminal cross-linking telopeptide of type I collagen generated by matrix metalloproteinases (CTX-MMP), tartrate-resistant acid phosphatase isoform 5b (TRACP5b), receptor-activated nuclear factor κB ligand (RANKL), osteoprotegerin (OPG), and sclerostin. Clinical outcomes were scintigraphic progression during/after therapy, change in bone scan index (BSI), occurrence of SSE, and OS. RESULTS: A total of 55 mCRPC patients were included. There was a significant linear association between skeletal extent of disease and CTX-MMP, PINP, BALP, and osteocalcin. No significant association between dynamics in BSI and BMM were detected. Median OS for the cohort was 14 months (95% CI: 10.7-16.8). Baseline levels of Log2-CTX-MMP (HR = 2.15 (95%CI: 1.1-4.1)) and Log2-BALP (HR = 1.59 (95%CI: 1.1-2.1)) were associated with OS. Patients with increasing CTX-MMP during therapy had significantly shorter OS (Median OS = 4 mo. (95%CI: 2.3-5.7)) than patients with stable or decreasing CTX-MMP (Median OS = 12 mo. (95%CI: 10.1-13.9), P < 0.001). CONCLUSION: BMM are significantly associated with scintigraphic extent of skeletal disease and OS in patients with mCRPC. Particularly, the bone resorption marker CTX-MMP is a promising surrogate marker for prediction of outcome in patients receiving Radium-223 therapy and could potentially improve selection of patients for therapy and assessment of response. TRIAL REGISTRATION: Clinicaltrials.gov, NCT03247010. Registered 10th of August 2017, https://clinicaltrials.gov/study/NCT03247010?term=NCT03247010&rank=1 .
引用
- Fosbøl MØ, Jørgensen NR, Petersen PM, et al. Biomarkers of bone metabolism in [223Ra] RaCl2 therapy - association with extent of disease and prediction of overall survival. EJNMMI Res. 2024. PMID: 39361218. doi:10.1186/s13550-024-01155-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。